A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

While RFK Jr. is likely to lead the Department of HHS, he will be limited in his ability to stop the continued innovation and ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...